A Prospective, Double-Blind, Randomized, Controlled Clinical Trial in the Gingivitis Prevention with an Oligomeric Proanthocyanidin Nutritional Supplement.

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

Who Took Part

The study group was 20 patients.

The age groups tagged for this paper are adults, both men and women.

A prospective, double-blind, randomized, controlled clinical trial was carried out on 20 patients; it is divided into an experimental group and a control group after fulfilling the selection criteria.

Patients had to come 4 times during the study to register the Silness and Löe index, the gingival bleeding index, the plaque index, the inflammatory crevicular fluid study (IL6), and the changes in the brightness of the gingiva.

How the Study Was Run

In design terms this was a randomized and double-blind study.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the patients nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.

No complementary hygiene methods were allowed during the 21 days.

What Was Measured

The subject headings attached to it are Dental Plaque, Dietary Supplements, Gingivitis, Interleukin-6 and Proanthocyanidins.

What This Means in Plain Language

The paper is a randomized and double-blind study of Copper (Supplement) in 20 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2017 (Mediators of inflammation), a journal based in United States.

More context: the Copper (Supplement) compound page, all human trials.